科研之友
微信
新浪微博
Facebook
分享链接
摘要
Zycose is a newly released (2006) combined medication containing folic acid (1 mg) benfotiamine (150 mg) and benzamine (850 mg), a proprietary blend of para-aminobenzoic acid (PABA), vitamin E and a-lipoic acid (ALA). Zycose protects vascular, retinal and kidney function by improving cellular health and promoting peripheral nerve health in people with diabetes. Zycose's therapeutic benefit is believed to be due to the additive effects of its compounds on lowering homocysteine levels (folic acid), reducing the production of advanced glycation end products (benfotiamine), improving endothelial folic acid, benfotiamine, ALA), reducing oxidative stress (ALA, vitamin E) and reducing carbonyl stress (benzamine). The complex composition of Zycose allows the therapeutic intervention of several hyperglycemia-mediated disorders. The compound consists mainly of vitamins, therefore explaining, in part, the good safety profile and reduced adverse effects.
- 出版日期2008-10
